Literature DB >> 17967158

Clinical consequences of polypharmacy in elderly: expect the unexpected, think the unthinkable.

Joel A Salazar1, Ivy Poon, Mridula Nair.   

Abstract

Multiple medication use has been coined 'polypharmacy'. Polypharmacy is highly prevalent in older patients secondary to the increased number of co-morbid disease states with ageing. Existing practice guidelines recommend multiple drug use for certain chronic diseases (i.e., HIV, tuberculosis, hypertension, etc.). A polypharmacologic approach for certain diseases has been shown to improve therapeutic response, decrease morbidity and mortality. On the contrary, polypharmacy may induce iatrogenic complications that are often unseen prior to the initiation of medicinal regimens. This paper will review the potential clinical consequences of polypharmacy in the elderly and common medication administration errors that may occur. Consequences of polypharmacy include adverse drug effects, drug-drug interactions, disease-drug interactions, food-drug interactions, nutraceutical-drug interactions and medication cascade effect. Medication administration errors, such as phonetic confusion, flip-flopping dosing errors and pill visual-cue errors, are also reviewed. Prescribing for the elderly, whose medications are vast in number, is often uncharted physiologic territory. The clinician must expect the unexpected and think of the unthinkable in the geriatric patient, when dealing with polypharmacy and the potential consequences.

Entities:  

Mesh:

Year:  2007        PMID: 17967158     DOI: 10.1517/14740338.6.6.695

Source DB:  PubMed          Journal:  Expert Opin Drug Saf        ISSN: 1474-0338            Impact factor:   4.250


  44 in total

Review 1.  Routine deprescribing of chronic medications to combat polypharmacy.

Authors:  Doron Garfinkel; Birkan Ilhan; Gulistan Bahat
Journal:  Ther Adv Drug Saf       Date:  2015-12

Review 2.  Cardiovascular drug therapy in the elderly: benefits and challenges.

Authors:  Jerome L Fleg; Wilbert S Aronow; William H Frishman
Journal:  Nat Rev Cardiol       Date:  2010-10-26       Impact factor: 32.419

3.  Revisiting medication use in a frail 93-year-old man experiencing possible adverse effects.

Authors:  Barbara Farrell; Anne Monahan; Wade Thompson
Journal:  CMAJ       Date:  2013-10-21       Impact factor: 8.262

4.  Drug interaction presenting as acute abdomen.

Authors:  Rajesh Pendlimari; Rajeswari Anaparthy; Aravind Sugumar
Journal:  World J Gastrointest Pharmacol Ther       Date:  2010-02-06

Review 5.  Effect of age on drug metabolism in women with breast cancer.

Authors:  Jasmeet C Singh; Stuart M Lichtman
Journal:  Expert Opin Drug Metab Toxicol       Date:  2015-05       Impact factor: 4.481

Review 6.  Clinical consequences of polypharmacy in elderly.

Authors:  Robert L Maher; Joseph Hanlon; Emily R Hajjar
Journal:  Expert Opin Drug Saf       Date:  2013-09-27       Impact factor: 4.250

7.  Use of hormonal therapy in senior breast cancer patients treated with or without radiotherapy.

Authors:  S P Krotneva; A Ramjaun; K E Reidel; T Eguale; N Trabulsi; N Mayo; R Tamblyn; A N Meguerditchian
Journal:  Curr Oncol       Date:  2014-02       Impact factor: 3.677

8.  Quality of prescribing in community-dwelling elderly patients in France: an observational study in community pharmacies.

Authors:  E Bourcier; F Mille; V Brunie; V Korb-Savoldelli; C Lafortune; M Buyse; C Fernandez; P Hindlet
Journal:  Int J Clin Pharm       Date:  2017-09-14

9.  Evaluation of the safety and efficacy of pregabalin in older patients with neuropathic pain: results from a pooled analysis of 11 clinical studies.

Authors:  David Semel; T Kevin Murphy; Gergana Zlateva; Raymond Cheung; Birol Emir
Journal:  BMC Fam Pract       Date:  2010-11-05       Impact factor: 2.497

Review 10.  Medications associated with falls in older people: systematic review of publications from a recent 5-year period.

Authors:  Hyerim Park; Hiroki Satoh; Akiko Miki; Hisashi Urushihara; Yasufumi Sawada
Journal:  Eur J Clin Pharmacol       Date:  2015-09-26       Impact factor: 2.953

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.